Avalo Therapeutics Inc (AVTX)

$12.78

+0.27

(+2.14%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $12.39
    $13.00
    $12.78
    downward going graph

    3.05%

    Downside

    Day's Volatility :4.69%

    Upside

    1.69%

    downward going graph
  • $3.95
    $77.57
    $12.78
    downward going graph

    69.09%

    Downside

    52 Weeks Volatility :94.91%

    Upside

    83.52%

    downward going graph

Returns

PeriodAvalo Therapeutics IncIndex (Russel 2000)
3 Months
7.57%
0.0%
6 Months
197.15%
0.0%
1 Year
-83.19%
0.0%
3 Years
-99.85%
-17.0%

Highlights

Market Capitalization
13.4M
Book Value
- $108.83
Earnings Per Share (EPS)
-51.0
Wall Street Target Price
35.0
Profit Margin
0.0%
Operating Margin TTM
-1372.05%
Return On Assets TTM
-15.54%
Return On Equity TTM
-524.01%
Revenue TTM
1.4M
Revenue Per Share TTM
3.02
Quarterly Revenue Growth YOY
-36.3%
Gross Profit TTM
-7.9M
EBITDA
-19.7M
Diluted Eps TTM
-51.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-28.11
EPS Estimate Next Year
-1.0
EPS Estimate Current Quarter
-1.18
EPS Estimate Next Quarter
-0.19

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Avalo Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 173.87%

Current $12.78
Target $35.00

Technicals Summary

Sell

Neutral

Buy

Avalo Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Avalo Therapeutics Inc
Avalo Therapeutics Inc
-5.66%
197.15%
-83.19%
-99.85%
-99.85%
Moderna, Inc.
Moderna, Inc.
-9.73%
21.69%
-3.08%
-61.31%
759.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
2.19%
14.34%
48.43%
82.37%
258.01%
Novo Nordisk A/s
Novo Nordisk A/s
-7.8%
21.53%
62.25%
194.33%
441.74%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.55%
12.21%
36.13%
144.99%
180.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Avalo Therapeutics Inc
Avalo Therapeutics Inc
NA
NA
NA
-28.11
-5.24
-0.16
NA
-108.83
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.06
32.06
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.67
31.67
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Avalo Therapeutics Inc
Avalo Therapeutics Inc
Sell
$13.4M
-99.85%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
759.82%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$119.6B
258.01%
32.06
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
441.74%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
180.32%
31.67
39.46%

Insights on Avalo Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 236.0K → 571.0K (in $), with an average increase of 58.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -5.22M → -121.29M (in $), with an average decrease of 720.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 62.3% return, outperforming this stock by 145.5%

Institutional Holdings

  • Ikarian Capital, LLC

    4.51%
  • Sio Capital Management, LLC

    0.98%
  • Affinity Asset Advisors, LLC

    0.97%
  • UBS Group AG

    0.75%
  • ADAR1 Capital Management LLC

    0.58%
  • Natixis SA

    0.24%

Company Information

cerecor inc. is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. we are a delaware corporation, organized in april 2011 in partnership with various laboratories and research institutes at johns hopkins medical institute ("jhmi"). cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. we acquire rights to early stage therapeutic technologies ("assets") from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.

Organization
Avalo Therapeutics Inc
Employees
19
CEO
Dr. Garry A. Neil M.D.
Industry
Miscellaneous

FAQs